Compare · OPCH vs VSEE
OPCH vs VSEE
Side-by-side comparison of Option Care Health Inc. (OPCH) and VSee Health Inc. (VSEE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OPCH and VSEE operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- OPCH is the larger of the two at $3.41B, about 632.1x VSEE ($5.4M).
- Over the past year, OPCH is down 25.5% and VSEE is down 92.8% - OPCH leads by 67.4 points.
- VSEE has been more active in the news (5 items in the past 4 weeks vs 4 for OPCH).
- OPCH has more recent analyst coverage (16 ratings vs 1 for VSEE).
- Company
- Option Care Health Inc.
- VSee Health Inc.
- Price
- $21.73-1.61%
- $0.10-2.00%
- Market cap
- $3.41B
- $5.4M
- 1M return
- +0.56%
- -20.55%
- 1Y return
- -25.45%
- -92.81%
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 5
- Recent ratings
- 16
- 1
Option Care Health Inc.
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides immunoglobulin infusion therapies for the treatment of immune deficiencies; anti-infective therapies and services; home infusion services to treat heart failures; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders; and immunoglobulin infusion therapies. It also offers infusion therapies for bleeding disorders; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications. In addition, the company offers therapies that women need to survive and thrive through high-risk pregnancies; treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; and nursing services. The company is headquartered in Bannockburn, Illinois.
Latest OPCH
- Option Care Health downgraded by Stephens with a new price target
- Option Care Health to Announce Second Quarter 2026 Financial Results and Host Conference Call
- EVP Sp Sales & Solutions Bhatia Prateek was granted 39,795 shares (SEC Form 4)
- SEC Form 3 filed by new insider Bhatia Prateek
- Goldman initiated coverage on Option Care Health with a new price target
- Option Care Health Appoints Robert Okunski as Vice President, Investor Relations
- Option Care Health Awarded TIME's World's Most Impactful Companies 2026 Ranking
- Director Bierbower Elizabeth D was granted 8,997 shares, increasing direct ownership by 38% to 32,871 units (SEC Form 4)
- Director Deckmann Natasha was granted 9,841 shares, increasing direct ownership by 44% to 32,002 units (SEC Form 4)
- Director Kraemer Harry M Jansen Jr was granted 21,076 shares, increasing direct ownership by 5% to 471,076 units (SEC Form 4)
Latest VSEE
- VSee Health Vision for AI-Enabled Enterprise Infrastructure as the Next Frontier of Hospital Operations
- SEC Form PRE 14A filed by VSee Health Inc.
- VSee Health Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events
- VSee Health CEO Issues Shareholder Update as Company Focuses on iDoc TeleHealth Solutions for Revenue Growth and Profitability
- VSee Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 424B3 filed by VSee Health Inc.
- VSee Health Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation
- VSee Health Realizes 20X Expansion of its Hospital Network to 58 Locations
- VSee Health Highlights Business Operations and Financial Success After Recent Strategic Sale
- VSee Health Completes Strategic Separation of VSee Lab, Retires Approximately 7% of Outstanding Shares, and Transitions to Single CEO Leadership